دورية أكاديمية
Treatment outcome after radiochemotherapy in anal cancer patients staged with 18F-FDG-PET-CT
العنوان: | Treatment outcome after radiochemotherapy in anal cancer patients staged with 18F-FDG-PET-CT |
---|---|
المؤلفون: | L.H. Braun, C.P. Reinert, D. Zips, K. Nikolaou, C. Pfannenberg, C. Gani |
المصدر: | Clinical and Translational Radiation Oncology, Vol 24, Iss , Pp 83-87 (2020) |
بيانات النشر: | Elsevier, 2020. |
سنة النشر: | 2020 |
المجموعة: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | Anal cancer, Radiotherapy, PET, Radiochemotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | Background: Anal cancer (AC) is a malignancy with increasing incidence and commonly treated with radiochemotherapy. Positron-emission tomography-computed tomography (PET/CT) has been shown to improve treatment outcome in various oncological diseases, however, for AC long-term outcome data is sparse. The aim of the present study is therefore to report outcomes in our cohort of PET/CT staged AC patients treated with radiochemotherapy. Methods: Patients with AC who were treated with radiochemotherapy in curative intent were included in this retrospective study if a PET/CT scan was performed pre-therapeutically. Information from PET/CT was considered for nodal and primary target volume definition. Radiotherapy dose to the primary tumor was 50–66 Gy and concomitant chemotherapy included 5-fluorouracil and mitomycin-C. The uptake of 18F-fluorodeoxyglucose (FDG) was quantified using 50%-isocontour volumes of interests (VOIs) and measuring the standardized uptake value (SUV) and the metabolic tumor volume (MTV).18F-FDG uptake was correlated with baseline clinical parameters and long-term oncological outcome. Survival estimates were determined according to Kaplan-Meier. Results: A total of 60 patients were included in this study. Estimates for three-year overall survival (OS) and disease free survival (DFS) were 94.5% and 80%. Five patients developed local (n = 2) or locoregional and local (n = 3) failure. Baseline PET/CT related parameters correlated with primary tumor stage, nodal stage and tumor grading. DFS was independent of T-stage, N-stage and baseline 18F-FDG-uptake. Conclusion: In this cohort of PET/CT staged AC patients, excellent outcomes for DFS were seen. PET-based markers of tumor burden correlate with local stage of AC, however, are not of prognostic relevance for disease-free survival. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2405-6308 |
Relation: | http://www.sciencedirect.com/science/article/pii/S2405630820300574; https://doaj.org/toc/2405-6308 |
DOI: | 10.1016/j.ctro.2020.06.008 |
URL الوصول: | https://doaj.org/article/851489e93793414b90e1ae8b0bd3bfde |
رقم الأكسشن: | edsdoj.851489e93793414b90e1ae8b0bd3bfde |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 24056308 |
---|---|
DOI: | 10.1016/j.ctro.2020.06.008 |